Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 7Triple Negative Breast Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Advanced Solid Tumors 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Fallopian Tube Neoplasms 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1Advanced Cancer 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × fluzoparib × Clear all
NCT04193319 2019-12-10

Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
20 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡